Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017

Details for Mechanism ID: 16752
Country/Region: Ethiopia
Year: 2016
Main Partner: Amhara Regional Health Bureau
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $7,878,649 Additional Pipeline Funding: $461,673

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,246,776
Care: TB/HIV (HVTB) $278,127
Care: Pediatric Care and Support (PDCS) $164,143
Laboratory Infrastructure (HLAB) $222,308
Strategic Information (HVSI) $206,514
Health Systems Strengthening (OHSS) $75,676
Biomedical Prevention: Blood Safety (HMBL) $50,927
Testing: HIV Testing and Counseling (HVCT) $116,941
Sexual Prevention: Other Sexual Prevention (HVOP) $131,382
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $532,520
Treatment: Adult Treatment (HTXS) $3,923,049
Treatment: Pediatric Treatment (PDTX) $930,286
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 1
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 584
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 477
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 595
GEND_GBV Number of people receiving post-GBV care 2017 1,049
GEND_GBV Sum of Age/Sex Disaggregates 2017 1
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 107,997
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 212
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 110,577
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 221
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 768,702
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 1,646
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 434,061
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 417
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 1,427,743
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 42
HTS_TST Service Delivery Point (Facility): Inpatient 2017 126,170
HTS_TST Service Delivery Point (Facility): Inpatient 2017 4
HTS_TST Service Delivery Point (Facility): Other PITC 2017 82,580
HTS_TST Service Delivery Point (Facility): Other PITC 2017 2
HTS_TST Service Delivery Point (Facility): Outpatient 2017 564,428
HTS_TST Service Delivery Point (Facility): Outpatient 2017 12
HTS_TST Service Delivery Point (Facility): PMTCT 2017 370,968
HTS_TST Service Delivery Point (Facility): PMTCT 2017 16
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 94,526
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 2
HTS_TST Service Delivery Point (Facility): VCT 2017 261,800
HTS_TST Service Delivery Point (Facility): VCT 2017 6
HTS_TST Sum of Aggregated Age/Sex <15 2017 218,574
HTS_TST Sum of Aggregated Age/Sex <15 2017 433
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 1,202,763
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 2,063
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 1,421,337
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 2,496
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 807
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 947
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 9,959
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 11
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 4,646
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 4,691
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 4,691
KP_PREV Total estimated number of key population in the catchment area 2017 31,950
KP_PREV_den By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 30,712
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 24
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 24
LAB_PT CD4: Number of laboratories that perform this testing 2017 28
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 5
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 5
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 5
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 341
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 341
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 341
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 5
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 5
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 5
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 24
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 24
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 341
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program 2017 2
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that perform this testing 2017 2
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 3
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 18
PMTCT_ART Already on ART at beginning of current pregnancy 2017 81
PMTCT_ART Already on ART at beginning of current pregnancy 2017 2,306
PMTCT_ART New on ART 2017 10
PMTCT_ART New on ART 2017 1,692
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 3,405
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 323,709
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 24
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 3,505
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 6
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 876
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 33
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 4
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 71
PMTCT_EID Sum of Infant Age disaggregates 2017 30
PMTCT_EID Sum of Infant Age disaggregates 2017 4,381
PMTCT_STAT By: Known positives at entry 2017 84
PMTCT_STAT By: Known positives at entry 2017 2,625
PMTCT_STAT By: Number of new positives identified 2017 12
PMTCT_STAT By: Number of new positives identified 2017 1,801
PMTCT_STAT Number of new ANC and L&D clients 2017 3,512
PMTCT_STAT Number of new ANC and L&D clients 2017 348,785
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 3,405
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 323,709
PMTCT_STAT Sum of Positives Status disaggregates 2017 96
PMTCT_STAT Sum of Positives Status disaggregates 2017 4,426
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 32,763
PP_PREV Total number of people in the target population 2017 42,985
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 24
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 392
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 48
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 552
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 4
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 1,022
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 5
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 1,027
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 5
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 8,812
TB_SCREENDX [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 34
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) 2017 11
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 2,657
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 2017 10
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 2,651
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 13
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 3,522
TB_SCREENDX Screen Result: Screened Positive for TB 2017 12,586
TB_SCREENDX Screen Results: Screened Positive for TB 2017 49
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 23
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 19
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 277
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 71,875
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 162
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 44,368
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 4,238
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 4,737
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 481
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 125,746
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 751
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 4,781
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,001
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 6,037
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 12,570
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 13,652
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 112
TX_CURR Aggregated Age/Sex: <15 Female 2017 4,515
TX_CURR Aggregated Age/Sex: <15 Male 2017 5,035
TX_CURR Aggregated Age/Sex: 15+ Female 2017 1
TX_CURR Aggregated Age/Sex: 15+ Female 2017 78,647
TX_CURR Aggregated Age/Sex: 15+ Male 2017 47,244
TX_CURR Aggregated Age/Sex: 15+ Male 2017 1
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 135,752
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 2
TX_CURR Sum of Aggregated Age/Sex <15 2017 9,550
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 2
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 125,891
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 2
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 135,441
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 894
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 1,064
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 8,531
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 4,967
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 15,487
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 15,456
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 1
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 89,119
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 1
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 71,309
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 2,463
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 2,734
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 41,037
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 1
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 25,071
TX_PVLS Numerator: Indication: Routine 2017 1
TX_PVLS Numerator: Indication: Routine 2017 57,036
TX_PVLS Numerator: Indication: Targeted 2017 14,247
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 5
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 3,047
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 5
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 3,398
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 69
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 51,026
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 39
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 31,212
TX_PVLS_den Denominator: Indication: Routine 2017 1
TX_PVLS_den Denominator: Indication: Routine 2017 71,307
TX_PVLS_den Denominator: Indication: Targeted 2017 17,813
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 505
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 603
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,826
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,174
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 10,110
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 20
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 11,384
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 573
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 683
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 11
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,567
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,578
Cross Cutting Budget Categories and Known Amounts Total: $1,681,734
Food and Nutrition: Policy, Tools, and Service Delivery $162,081
Renovation $900,000
Motor Vehicles: Purchased $520,000
Key Populations: Sex Workers $66,553
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: Gender Based Violence (GBV) $33,100
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation